Table 4.
Factors associated with disease-specific survival
| Variable | Total (n) |
Median DSS (mo) |
Univariate HR (95% CI) |
Univariate p-value |
Multivariable HR (95% CI) |
Multivariable p-value |
|---|---|---|---|---|---|---|
| Age at tertiary cytoreduction | ||||||
| <55 years | 42 | 46.0 | ref | |||
| ≥55 years | 72 | 72.9 | 0.79 (0.46-1.35) | 0.38 | ||
| Stage at diagnosis | ||||||
| I | 10 | 113.0 | ref | |||
| II | 16 | 80.7 | 1.73 (0.51-5.95) | 0.38 | ||
| III | 76 | 46.0 | 2.60 (0.92-7.33) | 0.07 | ||
| IV | 12 | 83.8 | 2.11 (0.52-8.61) | 0.30 | ||
| Grade | ||||||
| Low grade | 14 | 272.9 | ref | 0.08 | ||
| High grade | 100 | 54.7 | 3.55 (1.25-10.1) | 0.017* | 2.61 (0.89-7.62) | |
| Histology | ||||||
| Serous | 86 | 57.5 | ref | |||
| Endometrioid | 10 | 32.3 | 1.02 (0.45-2.34) | 0.96 | ||
| Clear Cell | 4 | 72.9 | 0.50 (0.07-3.68) | 0.50 | ||
| Carcinosarcoma | 3 | 12.4 | 23.45 (5.78-95.1) | <0.001* | ||
| Mucinous | 5 | - | 0.17 (0.02-1.26) | 0.082 | ||
| Other | 2 | 41.4 | 1.53 (0.21-11.24) | 0.68 | ||
| Mixed | 4 | 60.4 | 0.66 (0.16-2.75) | 0.57 | ||
| Serous | ||||||
| Non-serous | 28 | 60.4 | ref | |||
| Serous | 86 | 57.5 | 1.19 (0.65-2.19) | 0.58 | ||
| BRCA status | ||||||
| Negative | 44 | 72.9 | ref | |||
| Any BRCA | 22 | - | 0.59 (0.21-1.64) | 0.31 | ||
| Initial cytoreduction | ||||||
| ≤1 cm residual | 92 | 60.1 | ref | |||
| >1 cm residual | 9 | 46.0 | 1.34 (0.57-3.17) | 0.50 | ||
| Secondary cytoreduction | ||||||
| CGR | 75 | 57.5 | ref | |||
| Any residual | 36 | 60.3 | 0.98 (0.57-1.68) | 0.93 | ||
| Time to first recurrence | ||||||
| <2 years | 44 | 43.5 | ref | |||
| ≥2 years | 64 | 83.8 | 0.52 (0.30-0.90) | 0.019* | ||
| Treatment-free interval | ||||||
| ≤1 year | 40 | 44.2 | ref | <0.02 | ||
| >1 year | 73 | 60.4 | 0.49 (0.29-0.84) | 0.009* | 0.49 (0.28-0.85) | |
| Time from secondary cytoreduction | ||||||
| <2 years | 53 | 43.5 | ref | |||
| ≥2 years | 61 | 79.5 | 0.54 (0.31-0.92) | 0.022* | ||
| Platinum sensitivity | ||||||
| Sensitive | 101 | 60.3 | ref | <0.02 | ||
| Resistant | 13 | 18.0 | 4.41 (2.04-9.52) | <0.001* | 2.94 (1.22-7.07) | |
| CA-125 prior to tertiary cytoreduction (continuous) | 89 | 1.001 (1.000-1.001) | 0.193 | |||
| Residual disease at tertiary cytoreduction | ||||||
| CGR | 102 | 60.3 | ref | 0.003 | ||
| Any residual | 12 | 27.5 | 4.84 (2.05-11.43) | 0.02* | 3.71 (1.59-8.70) | |
| Sites of recurrence | ||||||
| Single | 51 | 79.5 | ref | |||
| Multiple | 63 | 46.0 | 1.45 (0.85-2.49) | 0.18 | ||
| Cytotoxic therapy after tertiary cytoreduction | ||||||
| Cytotoxic | 72 | 57.5 | ref | |||
| No cytotoxic | 12 | 60.1 | 1.14 (0.66-1.94) | 0.64 | ||
DSS, disease-specific survival; CGR, complete gross resection
*
statistically significant